Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes ...

Two vets have won £200 of BEVA CPD vouchers in a prize draw competition on Dechra’s stand at BEVA (British Equine Veterinary ...

GE Healthcare's move into theranostics marks a major advance in cancer care, promising to optimize treatment and patient ...

First once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors ...

The FDA has announced changes to the Prescription Drug User Fee Act (PDUFA) dates for Amgen and Intercept Pharmaceuticals, ...

Abbott is making significant strides in the diabetes technology sector, with CEO Robert Ford highlighting the potential of continuous glucose monitors (CGMs) to reach a wider market. This growth is ...

Bayer has embarked on a significant move to expand its pharmaceutical influence by applying for approval from the European Medicines Agency (EMA) for its new menopause drug, elinzanetant. Targeted at ...

Bayer a entrepris une démarche significative pour étendre son influence pharmaceutique en demandant l’approbation de l’Agence Européenne des Médicaments (EMA) pour son nouveau médicament contre la ...

Alleo Labs, based in San Francisco, has partnered with Dundee’s Ubiquigent Limited to modernise drug discovery processes focusing on deubiquitinases (DUBs). This strategic alliance uses Alleo’s AI ...

BioAffinity Technologies’ (Nasdaq: BIAF) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the peer-reviewed paper, “Implementation of ...

Refeyn, the company behind pioneering mass photometry technologies, has taken another step to assure mass photometry is a simpler, more efficient bioanalytics tool with the release of a powerful ...

Danish pharmaceutical company Lundbeck is making waves in the biopharma industry with its $2.6 billion acquisition of the biotechnology firm Longboard Pharmaceuticals. This strategic move targets the ...